Life science researchers and drug discovery scientists today work in what, in my view, will be remembered in the future as the beginning of a “golden era” where the power of genetic information is connected to a wide range of other healthcare and lifestyle data to support better understanding of disease etiology
More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use. (Complete article on page 21)
Interview with Marilyn Matz, CEO and Co-founder at Paradigm4, and 2020 NACD Directorship 100™ honoree, and her colleague Dr. Zachary Pitluk, VP of Life Sciences and Health Care at Paradigm4. Founded by renowned database researcher, Turing Award laureate MIT Professor Michael Stonebraker, Paradigm4 is not just any data analytics company
New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam.
